Stada Arzneimittel (SAZ) Given a €74.40 Price Target by Nord/LB Analysts

Nord/LB set a €74.40 ($91.85) price objective on Stada Arzneimittel (ETR:SAZ) in a research note issued to investors on Friday morning. The firm currently has a sell rating on the stock.

A number of other analysts have also recently commented on SAZ. Independent Research set a €89.00 ($109.88) target price on Stada Arzneimittel and gave the stock a neutral rating in a research report on Wednesday. Cfra set a €70.00 ($86.42) target price on Stada Arzneimittel and gave the stock a sell rating in a research report on Monday, March 12th. Warburg Research set a €74.40 ($91.85) target price on Stada Arzneimittel and gave the stock a sell rating in a research report on Friday, March 9th. Finally, Commerzbank set a €66.25 ($81.79) target price on Stada Arzneimittel and gave the stock a sell rating in a research report on Wednesday, December 20th. Five research analysts have rated the stock with a sell rating and two have assigned a hold rating to the stock. Stada Arzneimittel currently has an average rating of Sell and a consensus target price of €73.49 ($90.73).

How to Become a New Pot Stock Millionaire

Shares of Stada Arzneimittel (ETR SAZ) opened at €83.90 ($103.58) on Friday. Stada Arzneimittel has a 52-week low of €53.41 ($65.94) and a 52-week high of €90.24 ($111.41). The company has a market capitalization of $5,270.00 and a PE ratio of 61.24.

TRADEMARK VIOLATION NOTICE: This news story was first published by Ticker Report and is the property of of Ticker Report. If you are viewing this news story on another publication, it was illegally stolen and republished in violation of U.S. & international copyright law. The legal version of this news story can be read at https://www.tickerreport.com/banking-finance/3295865/stada-arzneimittel-saz-given-a-74-40-price-target-by-nord-lb-analysts.html.

About Stada Arzneimittel

STADA Arzneimittel Aktiengesellschaft engages in the development and marketing of pharmaceutical products for the health care and pharmaceutical markets worldwide. It operates through two segments, Generics and Branded Products. The Generics segment provides various generic active ingredients, including Tilidin Naloxone for pain; Atorvastatin for elevated cholesterol levels; Epoetin zeta for anemia; Diclofenac for pain/inflammation; and Pantoprazole for gastric ulcer/reflux.

Analyst Recommendations for Stada Arzneimittel (ETR:SAZ)

Receive News & Ratings for Stada Arzneimittel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stada Arzneimittel and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Zacks: Analysts Expect Bank Of Princeton  to Post $0.51 EPS
Zacks: Analysts Expect Bank Of Princeton to Post $0.51 EPS
Energen  Earns Buy Rating from Stephens
Energen Earns Buy Rating from Stephens
Smart Sand  Expected to Post Earnings of $0.08 Per Share
Smart Sand Expected to Post Earnings of $0.08 Per Share
JetPay  Getting Favorable News Coverage, Accern Reports
JetPay Getting Favorable News Coverage, Accern Reports
Glen Burnie Bancorp  Receives News Sentiment Rating of -0.08
Glen Burnie Bancorp Receives News Sentiment Rating of -0.08
MKS Instruments  Releases Q2 Earnings Guidance
MKS Instruments Releases Q2 Earnings Guidance


© 2006-2018 Ticker Report. Google+.